PHP
EIDX

Parkman Healthcare Partners’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Parkman Healthcare Partners’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,609
Closed -$2.84M – 104
2020
Q4 		$2.84M Sell
21,609
-19,482
-47% -$1.72M 0.73% 51
2020
Q3 		$2.08M Buy
41,091
+6
+0% +$270 0.55% 59
2020
Q2 		$1.96M Sell
41,085
-40,000
-49% -$1.86M 0.55% 57
2020
Q1 		$3.97M Sell
81,085
-126,186
-61% -$6.43M 1.84% 20
2019
Q4 		$11.9M Buy
+207,271
New +$10.3M 3.43% 7

Parkman Healthcare Partners's EIDX Position: Q1 2021 in Review

Parkman Healthcare Partners sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 21,609 shares — an estimated $2.84M sold.

Parkman Healthcare Partners first reported a position in EIDX in Q4 2019 and held it in 5 quarters. The position peaked at $11.9M in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Parkman Healthcare Partners reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 21,609 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.84M.
  • Parkman Healthcare Partners first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Parkman Healthcare Partners's Eidos Therapeutics, Inc. Common Stock position peaked at $11.9M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.